Soleno Therapeutics Inc. diskutieren

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $8.00 price target on the stock.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $19.00 price target on the stock.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Oppenheimer Holdings Inc. from $8.00 to $14.00. They now have an "outperform" rating on the stock.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Cantor Fitzgerald from $19.00 to $35.00. They now have an "overweight" rating on the stock.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Oppenheimer Holdings Inc. from $44.00 to $47.00. They now have an "outperform" rating on the stock.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $63.00 price target on the stock.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $93.00 price target on the stock.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $65.00 to $59.00. They now have an "outperform" rating on the stock.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) was upgraded by analysts at Baird R W to a "strong-buy" rating.

Soleno Therapeutics is an exciting biotech company with a promising lead drug candidate, DCCR, for the treatment of Prader-Willi syndrome. The recent submission of the NDA to the FDA is a significant milestone that could pave the way for the drug's approval and commercialization. Given the high unmet need in this rare disease and the positive clinical data on DCCR, I believe Soleno has a good chance of success. While there are always risks with drug development, the potential upside in this case seems to outweigh the risks. If DCCR gets approved, Soleno could see a significant boost in its valuation, which is why I'm cautiously optimistic about the company's future prospects.

Soleno Therapeutics Inc. has recently submitted a New Drug Application (NDA) to the FDA for its lead product candidate, DCCR (diazoxide choline) extended-release tablets, for the treatment of Prader-Willi syndrome (PWS). This is a significant milestone for the company, as PWS is a rare and complex genetic disorder that currently has limited treatment options. The submission of the NDA suggests that Soleno is making progress in its efforts to bring a potential new therapy to market. Additionally, the company has announced inducement grants to new employees, which could indicate that Soleno is expanding its team and resources to support the development and commercialization of DCCR. While there are still regulatory hurdles to overcome, the positive news surrounding Soleno's pipeline and growth suggests that the stock could be worth a closer look for investors interested in the rare disease space. Of course, as with any investment, it's important to do your own research and consider your risk tolerance before making a decision. But based on the information available, Soleno Therapeutics appears to be a company with promising potential that's worth keeping an eye on.

Soleno Therapeutics is an exciting biotech company that has recently submitted a New Drug Application (NDA) to the FDA for its lead product candidate, DCCR, for the treatment of Prader-Willi Syndrome (PWS). PWS is a rare and complex genetic disorder that causes uncontrollable hunger, obesity, and other health issues. If approved, DCCR could be a game-changer for patients and their families. The company's recent inducement grants to new employees suggest that they are gearing up for potential commercialization, which is a positive sign. With a current stock price of $40.46, I believe Soleno Therapeutics is poised for significant growth in the coming years. The potential for DCCR to address the unmet needs of PWS patients, coupled with the company's strategic positioning, makes this stock an attractive investment opportunity. Of course, as with any biotech stock, there are risks involved, but the potential rewards seem to outweigh the risks in this case. What do you think? Are you tempted to add Soleno Therapeutics to your portfolio?

Soleno Therapeutics has recently submitted a New Drug Application (NDA) to the FDA for its lead drug candidate, DCCR, for the treatment of Prader-Willi Syndrome (PWS). This is a significant milestone for the company and could potentially lead to the approval and commercialization of DCCR, which could be a game-changer for individuals living with PWS. The company has also granted inducement awards to eight new employees, indicating their commitment to expanding their team and advancing their pipeline. Given the unmet need in the PWS market and the promising data on DCCR, I believe Soleno Therapeutics is well-positioned for growth. While there are still regulatory hurdles to overcome, the submission of the NDA is a positive step forward, and I'm optimistic about the company's future prospects. It's worth keeping an eye on Soleno Therapeutics as they navigate the regulatory process and work towards potentially bringing a new treatment option to the PWS community.

Soleno Therapeutics is an exciting biotech company that has recently submitted a New Drug Application (NDA) to the FDA for its lead product, DCCR, for the treatment of Prader-Willi syndrome. Prader-Willi syndrome is a rare genetic disorder that causes insatiable hunger, and DCCR has shown promising results in clinical trials. If approved, DCCR could be a game-changer for those suffering from this debilitating condition. The company's recent inducement grants to new employees suggest that they are building a strong team to support the launch of DCCR, should it receive FDA approval. While there are always risks associated with drug development, the potential upside for Soleno Therapeutics is significant. I believe the company is well-positioned to capitalize on the unmet need in the Prader-Willi syndrome market, and I'm optimistic about its future prospects. Of course, as with any investment, it's important to do your own research and consult with a financial advisor before making a decision. But if you're looking to add a promising biotech stock to your portfolio, Soleno Therapeutics could be worth a closer look.

Soleno Therapeutics is a promising biotech company that has recently submitted a New Drug Application (NDA) to the FDA for its lead product candidate DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS). This is a significant milestone for the company, as PWS is a rare and complex genetic disorder with no approved treatments. If approved, DCCR could be a game-changer for individuals living with PWS, addressing the key symptom of hyperphagia (uncontrollable hunger). The company has also granted inducement awards to eight new employees, indicating its commitment to expanding its team and advancing its pipeline. With a current stock price of $46.88, I believe Soleno Therapeutics presents an attractive investment opportunity, as the successful approval and commercialization of DCCR could lead to substantial upside potential. While there are always risks associated with drug development, Soleno's focus on rare diseases and its progress with DCCR make it a compelling stock to consider adding to one's portfolio. Remember, though, to do your own research and consult with a financial advisor before making any investment decisions.

Soleno Therapeutics is a promising biopharmaceutical company that has recently submitted a New Drug Application (NDA) to the FDA for its lead product, DCCR (diazoxide choline) extended-release tablets, for the treatment of Prader-Willi syndrome (PWS). PWS is a rare genetic disorder that affects appetite, growth, and metabolism, and there is a significant unmet need for effective treatments. Soleno's submission of the NDA is a major milestone, and if approved, DCCR could become a game-changer for individuals living with PWS. The company's recent inducement grants to new employees suggest that they are building a strong team to support the potential launch of DCCR. Considering the positive developments and the significant addressable market for PWS treatments, I believe Soleno Therapeutics is well-positioned for growth, and the current stock price presents an attractive entry point for investors.

Soleno Therapeutics has just submitted a New Drug Application (NDA) to the FDA for its lead product candidate DCCR, which is being developed for the treatment of Prader-Willi Syndrome (PWS). This is a significant milestone for the company, as DCCR has the potential to become a game-changer in the management of this rare and complex genetic disorder. Given the unmet medical need and the positive data from their clinical trials, I believe DCCR could receive FDA approval and become a valuable addition to the treatment options for patients with PWS. Additionally, the company's recent inducement grants to new employees suggest they are building a strong team to support the commercialization of DCCR, should it be approved. While there are always risks associated with the regulatory process, I'm cautiously optimistic about Soleno's prospects and believe the stock could see further upside from the current price of $46.88.